Twist Bioscience rises on licensing deal for antibody discovery platform
Source: SeekingAlpha
2026-02-17 12:05:40 ET
More on Twist Bioscience
- Twist Bioscience: Liquid Biopsy And AI Tailwinds
- Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases
- Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript
- Twist Bioscience outlines $435M–$440M 2026 revenue target while accelerating AI-enabled discovery investments
- Twist Bioscience rises as fiscal 2026 revenue guidance raised
Read the full article on Seeking Alpha
For further details see:
Twist Bioscience rises on licensing deal for antibody discovery platform
Twist Bioscience Corporation
NASDAQ: TWST
TWST Trading
0.81% G/L:
$43.135 Last:
266,645 Volume:
$43.95 Open:
TWST Latest News
February 17, 2026 07:00:00 am
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
February 10, 2026 08:00:00 am
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
TWST Stock Data
$2,986,186,543
59,423,304
2.85%
91
N/A
Medical Diagnostics & Screening
Healthcare
US
South San Francisco
